Affimed N.V.
AFMDQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.98M
Close$
Share Statistics
| Market cap | $2.98 Million |
|---|---|
| Enterprise Value | $9.08 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -406.92% |
|---|---|
| Return on Assets | -175.10% |
| Return on Invested Capital | -304.65% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 10.35 |
| Enterprise Value to EBIT | -0.13 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.49 |
| Debt to Equity | 0.79 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 3, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$175,141
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$172,618
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Affimed N.V.
76 employees
CEO: Shawn Leland Affimed N.V. operates as a clinical-stage biopharmaceutical firm, dedicated to the discovery and advancement of immunotherapies targeting cancer across both the United States and Germany. Its primary therapeutic candidates include AFM13,...